Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Ark Med Soc ; 111(6): 110-1, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25654924

ABSTRACT

We present a case of a middle-aged patient presenting with acute onset abdominal pain and distension who had signs of bowel obstruction on physical exam. He was afebrile, hemodynamically stable with no peritoneal signs. Abdominal radiograph and CT scan were pathognomic for sigmoid volvulus. Through this case report we want to discuss the presentation, diagnosis, management options for sigmoid volvulus and importance of features suggestive of ischemic bowel that necessitates different management options.


Subject(s)
Abdominal Pain/diagnostic imaging , Colonoscopy/methods , Flatulence/diagnostic imaging , Intestinal Volvulus/diagnostic imaging , Tomography, X-Ray Computed/methods , Abdominal Pain/therapy , Acute Disease , Flatulence/therapy , Humans , Intestinal Volvulus/therapy , Male , Middle Aged
2.
Gulf J Oncolog ; (12): 7-10, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22773210

ABSTRACT

INTRODUCTION: Penile cancer is one of the most common genitourinary cancers encountered in developing countries like India. The incidence of carcinoma of the penis varies according to circumcision practice, hygienic standard, phimosis, the number of sexual partners, HPV infection, exposure to tobacco products, and other factors. The aim of the study was to study the clinic-epidemiological profile of penile cancer. MATERIALS AND METHODS: 54 patients were enrolled and studied from May 2005 to June 2006. Clinicoepidemiologic profile and patients' characteristics were assessed in a questionnaire including demographic data, presence of risk factors like smoking, phimosis, circumcision, history of promiscuity, history of sexually transmitted disease etc., clinical features, pathological features of tumor like size, site, appearance, histological type, grade, presence of lymph nodes, treatment performed and response. 5 year survival rates were also calculated. RESULTS: Of the 54 patients, about three-fourths patients were older than 50. About one quarter patients presented with phimosis and 20% patients had undergone circumcision after attaining adulthood. 70% patients were found to be smokers. Most patients presented with T2 disease whereas lymphadenopathy, both benign and malignant, was present in 55.5% and 76% patients in T1 and T2 patients respectively. 5 year survival rates were found to be 87% and 60% respectively in stage I and II respectively. CONCLUSION: penile cancer is one of the most common genitourinary cancer affecting mostly aged, uncircumcised males with history of smoking.Most patients present at advanced age and hence a national awareness campaign against this disease should be promoted.


Subject(s)
Penile Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Circumcision, Male , Humans , India/epidemiology , Male , Middle Aged , Neoplasm Staging , Penile Neoplasms/etiology , Penile Neoplasms/mortality , Penile Neoplasms/pathology , Risk Factors , Survival Rate
3.
Dig Dis Sci ; 57(1): 9-18, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21938486

ABSTRACT

Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are slow-growing but commonly advanced malignancies with increasing incidence and prevalence. While locoregional disease can be effectively managed with resection, treatment of recurrent, progressive or metastatic disease has until recently been limited to palliative embolization and cytoreducitve surgery, with cytotoxic chemotherapeutic agents being the last resort. However, novel molecular targeted therapies inhibiting malignant cell proliferation and neoangiogenesis, as well as new cytotoxic chemotherapy drugs and somatostatin analogues, are all being investigated for their potential use in advanced neuroendocrine tumors. Long-acting release forms of octreotide have been shown to not only improve symptoms in carcinoid syndrome but to also delay progression of gastrointestinal NETs. On the other hand, phase III trials have demonstrated everolimus (with octreotide) and sunitinib to increase progression-free survival in pancreatic NETs. Use of bevacizumab has also shown promise in a phase II study, and results of an ongoing phase III trial comparing it to interferon are eagerly expected. Use of radiolabeled somatostatin analogues is still under investigation, though several phase II studies are encouraging. New cytotoxic agents, most notably temozolomide and capecitabine, are already in use, but their relative effectiveness compared to streptozocin in pancreatic NETs is yet to be determined.


Subject(s)
Drug Therapy/trends , Gastrointestinal Neoplasms/drug therapy , Neuroendocrine Tumors/drug therapy , Pancreatic Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Cytotoxins/therapeutic use , Humans , Neoplasm Metastasis/drug therapy , Neoplasm Recurrence, Local/drug therapy
5.
Gynecol Oncol ; 79(1): 124-8, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11006044

ABSTRACT

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, malignant neoplasm that has recently been characterized. It has not been associated with a primary visceral organ. In women, cases are even more rare and often have some ovarian involvement. CASE: An 11-year-old girl presented with abdominal pain, nausea, and vomiting. A CT scan revealed a large heterogeneous pelvic mass with cystic components and an 8-cm midabdominal mass. During exploratory laparotomy, the patient was found to have a pelvic mass measuring 12. 9 cm replacing normal ovarian tissue. The midabdominal mass was also removed. Pathology, cytology, and immunohistochemistry confirmed a desmoplastic small round cell tumor. Even with aggressive surgical and medical intervention, the patient died 11 months after initial diagnosis. CONCLUSION: We present a rare small cell tumor that is associated with ovarian involvement. The prognosis in these patients is extremely poor and very few survivals have been reported.


Subject(s)
Ovarian Neoplasms/pathology , Child , Diagnosis, Differential , Female , Humans , Neoplasms, Adnexal and Skin Appendage/diagnosis , Ovarian Neoplasms/diagnosis
6.
Am J Obstet Gynecol ; 183(1): 18-21, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10920302

ABSTRACT

OBJECTIVES: Among women the association between heat shock protein immunity and cancer has been examined primarily for breast cancer. Autoantibodies to the 27-kd heat shock protein were detected in some patients with breast cancer but not in control subjects, and the presence of these antibodies was correlated with improved survival. We examined the relationship between autoimmunity to heat shock proteins and the diagnosis of malignancies of the female genital tract. STUDY DESIGN: Serum samples from women seen for possible gynecologic malignancies or returning for evaluation after surgery, radiation, chemotherapy, or a combination for gynecologic cancers were tested for immunoglobulin G antibodies to the 27-kd, 60-kd, 70-kd, and 90-kd heat shock proteins by enzyme-linked immunosorbent assay with the purified recombinant proteins bound to wells of a microtiter plate. Serum samples from women with no history of malignancies served as control preparations. RESULTS: Antibodies to the 27-kd heat shock protein were detected in only 1 of 29 healthy control subjects (3.4%) and 1 of 23 women whose lesions were benign (4.3%). In marked contrast, 39 of 96 women with gynecologic cancers (40.6%) had positive antibody detection (P =.0004 vs benign). The percentages of positive results seen for ovarian (17/34, 50%), endometrial (13/34, 38.2%), cervical and uterine (3/10, 30%), vaginal and vulvar (3/5, 60%), and other (3/13, 23.1%) cancers were not significantly different from each other. Similar prevalences of antibodies to the 27-kd heat shock protein were seen among patients with cancer who had untreated active disease and after treatment. Unlike the results with antibodies to the 27-kd heat shock protein there was no relationship between antibodies to the other heat shock proteins and any gynecologic cancer. CONCLUSION: Circulating autoantibodies to the 27-kd heat shock protein were found to be associated with malignancies of the female genital tract.


Subject(s)
Autoantibodies/blood , Genital Neoplasms, Female/immunology , Heat-Shock Proteins , Neoplasm Proteins/immunology , Adult , Aged , Endometrial Neoplasms/immunology , Female , HSP27 Heat-Shock Proteins , Humans , Middle Aged , Molecular Chaperones , Ovarian Neoplasms/immunology , Pregnancy , Uterine Cervical Neoplasms/immunology , Uterine Neoplasms/immunology , Vaginal Neoplasms/immunology , Vulvar Neoplasms/immunology
7.
Int J Cancer ; 87(6): 824-8, 2000 Sep 15.
Article in English | MEDLINE | ID: mdl-10956393

ABSTRACT

Heat-shock proteins promote cell survival under adverse environmental conditions. Synthesis of the 27-kDa (HSP27), 70-kDa (HSP70), and 90-kDa (HSP90) heat-shock proteins is increased in malignantly transformed cells and has been associated with tumor proliferation, metastasis, and resistance to chemotherapeutic agents. The increased expression of heat-shock proteins and their association with tumor-specific antigens may result in local immunity to the heat-shock proteins. We examined the occurrence of IgA antibodies to HSP27, HSP70, and HSP90 in the lower genital tracts of women with possible gynecologic cancers. Cervical samples were obtained from 119 consecutive women being evaluated for a gynecologic malignancy or returning for a follow-up examination following cancer treatment. Aliquots were tested for IgA anti-heat-shock protein antibodies by ELISA. Aliquots were also tested for IgG antibodies to HSP27 as well as for human papillomavirus. Anti-HSP27 IgA was detected in 85.7% of 21 women with endometrial cancer tested prior to diagnosis and in 41.1% of 17 women tested after treatment. In women with ovarian cancer, 77.8% of 9 women tested prior to diagnosis and 75.0% of 24 women evaluated after treatment were anti-HSP27 IgA-positive. Of 6 women with cervical cancer tested prior to diagnosis, 5 were positive for this antibody. None of 25 women with benign diagnoses or 46 healthy women were cervical IgA anti-HSP27-positive (P < 0.0001). In contrast, anti-HSP27 IgG was not associated with a gynecologic malignancy. HSP27 cervical antibodies were not associated with the presence of human papillomavirus. Cervical IgA antibodies to HSP90 were associated with ovarian cancer; antibodies to HSP70 were not cancer-associated. We conclude that cervical IgA antibodies to HSP27 may be indicators of a gynecologic malignancy.


Subject(s)
Antibodies, Neoplasm/analysis , Genital Neoplasms, Female/immunology , Heat-Shock Proteins/immunology , Immunoglobulin A/analysis , Neoplasm Proteins/immunology , Aged , Female , HSP70 Heat-Shock Proteins/immunology , HSP90 Heat-Shock Proteins/immunology , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...